Ning Yin, Muhammad AM, Syed ZH Bukhari and Syed A Ali
Melanoma is responsible for the most of skin cancer deaths each year. Standard therapies haven’t shown much efficacy against malignant melanoma. Therefore, new “individualized medicine” approaches are expected to overcome this deadly disease. Recent studies show that specific targeting of oncogenic signalling pathways using small molecule drugs in combinations or immuno-therapies have shown an improved advantage both in non-clinical and clinical research. This article will provide an overview of the progress in pathway targeting therapies in melanoma.